How Does This Veterinary Diagnostics Business Operate?
IDEXX Laboratories makes diagnostic and information tools used in veterinary and related health-care settings. The company sells instruments, consumables, and services that support testing and workflow in clinical environments. Its business is built around recurring usage of diagnostic systems and ongoing customer relationships. IDEXX operates at large scale, with a market value of about USD 45.1 billion.
Are Profits and Cash Flow Still Expanding?
FundamentalsIn 2025, reported in USD, IDEXX generated USD 4.3 billion of revenue, with EBIT of USD 1.36 billion and net income of USD 1.06 billion. Cash on hand was USD 180.1 million alongside USD 150.0 million of total debt.
Operating results remained highly profitable on a trailing basis, with a 61.80% gross margin and a 31.60% operating margin, translating into a 24.62% net profit margin. Revenue grew 10.4% year over year, and the cash flow proxy for the period was USD 1.24 billion, with depreciation and amortization of USD 145.2 million.
Is The Market Overpaying For Growth?
DCF / MultiplesAt USD 567.46, the stock trades above the range suggested by the discounted‑cash‑flow model. Headline multiples also reflect that richer pricing, with a 42.54 P/E and 30.39 EV/EBITDA on a trailing basis.
Strong Business, Stretched Valuation
TakeawayThe balance sheet looks lightly levered, but cash is not large. Today’s price assumes a lot from future cash generation. The case works if high margins and growth persist. It breaks if cash generation cools while valuation stays elevated.